This is the case, for instance, of chronic myelomonocytic leukemia (CMML), a mixed MDS/MPN neoplasm where TET2 mutations are present in up to 60% of patients [16,132] (Table 1). This evidence concerns the gene TET2 and chronic myelomonocytic leukemia.